Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Ethan Barnett"'
Autor:
Bastien Nguyen, Susan F. Slovin, Michael J. Morris, Dana E. Rathkopf, Jose Mauricio Mota, Philip W. Kantoff, Konrad H. Stopsack, Jessica Flynn, Daniel C. Danila, Jones T. Nauseef, David B. Solit, Wassim Abida, Ethan Barnett, Glenn Heller, Howard I. Scher, Nikolaus Schultz, Andreas Wibmer
Publikováno v:
JCO Precis Oncol
PURPOSE Alterations in DNA damage repair (DDR) genes occur in up to 25% of patients with metastatic castration-resistant prostate cancer (mCRPC) and may sensitize to platinum chemotherapy. We aimed to evaluate the efficacy of platinum-based chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48698e18ade0f59097ac1afbacbd790c
https://doi.org/10.1200/po.19.00346
https://doi.org/10.1200/po.19.00346
Autor:
Joseph D. Schonhoft, Nicole A. Schreiber, Ethan Barnett, Melissa Harvey, Audrey Gill, Howard I. Scher, Ryon P. Graf, David S.K. Lu, Rachel Krupa, Sarah Orr, Adam Jendrisak, Emily Carbone
Publikováno v:
Journal of Circulating Biomarkers, Vol 9, Iss 1, Pp 13-19 (2020)
Journal of Circulating Biomarkers
Journal of Circulating Biomarkers
Introduction: Here we describe the development of a protein immunofluorescent assay for the detection of nuclear-localized androgen receptor variant 7 (AR-V7) protein within circulating tumor cells (CTCs) identified in patient blood samples. Used in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ef68d81efc574f1285031ed5c5174a
https://doi.org/10.33393/jcb.2020.2163
https://doi.org/10.33393/jcb.2020.2163
Autor:
Melanie Hullings, Ryon P. Graf, Howard I. Scher, Ryan Dittamore, Emily Carbone, Ethan Barnett
Publikováno v:
Eur Urol
Background Proof of the clinical utility of a biomarker is when its use informs a management decision and improves patient outcomes relative to when it is not used. Objective To model the clinical benefit of the nuclear-localized androgen receptor sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38c7b42df0eb29e3fb1207006f9376f
https://doi.org/10.1016/j.eururo.2019.08.020
https://doi.org/10.1016/j.eururo.2019.08.020
Autor:
Ethan Barnett, Sungmin Woo, Timothy G. Perk, Rajkumar Munian-Govindan, Ojaswita Lokre, Ria N Gajar, Tatiana Erazo, Emily Carbone, Michael J. Morris, Hebert Alberto Vargas, Howard I. Scher
Publikováno v:
Journal of Clinical Oncology. 41:251-251
251 Background: The heterogeneity of individual sites of disease in prostate cancer is well recognized and increases over time as the therapies administered promote divergent evolution. In clinical practice, this is often depicted in radiology report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2adbdd9ae3db35892228137f758efe55
https://doi.org/10.1200/jco.2023.41.6_suppl.251
https://doi.org/10.1200/jco.2023.41.6_suppl.251
Publikováno v:
Trends Cancer
For decades, mathematical models have influenced how we schedule chemotherapeutics. More recently, mathematical models have leveraged lessons from ecology, evolution, and game theory to advance predictions of optimal treatment schedules, often in a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46587cc6f6252da22ca4c1090854fc72
https://pubmed.ncbi.nlm.nih.gov/35277375
https://pubmed.ncbi.nlm.nih.gov/35277375
Autor:
Daniel C. Danila, Ethan Barnett, Samantha E. Vasselman, Philip W. Kantoff, Susan F. Slovin, Michael J. Morris, Konrad H. Stopsack, Alexander Blum, Emily Carbone, Barbara Nweji, Wassim Abida, Niamh M. Keegan, Dana E. Rathkopf, Karen A. Autio
BackgroundRoutine clinical data from clinical charts are indispensable for retrospective and prospective observational studies and clinical trials. Their reproducibility is often not assessed.ObjectiveTo develop a prostate cancer-specific database wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3ea555e94b0c39193b0ee4f2eb817be
https://doi.org/10.1101/2021.09.20.21263842
https://doi.org/10.1101/2021.09.20.21263842
Publikováno v:
Clinical Chemistry. 66:3-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d13ff3513697d1109a5dc97f705c32d8
https://doi.org/10.1373/clinchem.2019.310854
https://doi.org/10.1373/clinchem.2019.310854
Autor:
Ethan Barnett, Emily Carbone, Niamh M. Keegan, Samantha E Vasselman, Barbara Nweji, Samir Zaidi, Howard I. Scher
Publikováno v:
Journal of Clinical Oncology. 40:5029-5029
5029 Background: The incidence of transformation to neuroendocrine prostate cancer (NEPC) has increased in castration resistant prostate cancer (CRPC) in parallel with treatment advances inhibiting androgen receptor signaling. The current understandi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c654762cffafebffef7d8c67e755837d
https://doi.org/10.1200/jco.2022.40.16_suppl.5029
https://doi.org/10.1200/jco.2022.40.16_suppl.5029
Autor:
J. Lu, Daniel C. Danila, Jimmy L. Zhao, Russell Z. Szmulewitz, C.H. dos Anjos, Susan Halabi, Emmanuel S. Antonarakis, Daniel J. George, Audrey Gill, Qian Yang, Joseph D. Schonhoft, Emily Carbone, Andrew J. Armstrong, Scott T. Tagawa, Rick Wenstrup, Howard I. Scher, Ethan Barnett, Jun Luo, Mithat Gonen
Publikováno v:
Eur J Cancer
To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e25fed0a58fbd99233cfc435e7f667
https://pubmed.ncbi.nlm.nih.gov/33894633
https://pubmed.ncbi.nlm.nih.gov/33894633
Autor:
Joseph D. Schonhoft, Angel E. Dago, Ryan Dittamore, Jimmy L. Zhao, Melanie Hullings, Mithat Gonen, Jerry Lee, Ethan Barnett, Adam Jendrisak, Yipeng Wang, Audrey Gill, Emily Carbone, Samuel F. Bakhoum, Mark Landers, Howard I. Scher, Ramsay Sutton
Publikováno v:
Cancer Res
Chromosomal instability (CIN) increases a tumor cell's ability to acquire chromosomal alterations, a mechanism by which tumor cells evolve, adapt, and resist therapeutics. We sought to develop a biomarker of CIN in circulating tumor cells (CTC) that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::752bdfef1da6f8dcab84a6c08482f6df
https://pubmed.ncbi.nlm.nih.gov/32816908
https://pubmed.ncbi.nlm.nih.gov/32816908